InBios International has received Emergency Use Authorization (EUA) from the FDA for its SCoV-2 Detect rapid test for COVID-19.

The qualitative immunoassay is designed to detect Immunoglobulin G (IgG) antibodies to the SARS-CoV-2 virus that causes COVID-19 infections.

The rapid test, which can use serum, plasma, venous whole blood or fingerstick whole blood samples, takes about 20 minutes to deliver results, according to the Seattle, Wash.-based company.